Ruxolitinib

• JAK inhibitor
• Indications include myelofibrosis, polycythemia, and steroid-refractory graft-versus-host disease
• Adverse effects include ecchymosis, headache, dizziness, abdominal pain, diarrhea, and fatigue, as well as anemia and thrombocytopenia and occasional neutropenia
  • May increase risk of herpes zoster infection
  • May increase risk of basal cell carcinoma and squamous cell carcinoma